|
9. Discontinued Operations
The components of loss from discontinued operations as reported in our condensed statements of operations and comprehensive loss were as follows:
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
September 30, 2020 |
|
September 30, 2020 |
|
|
|
(In thousands, except per share data) |
Revenue: |
|
|
|
|
|
|
Product revenue |
|
$ |
102 |
|
$ |
388 |
|
|
|
|
|
|
|
Costs and expenses: |
|
|
|
|
|
|
Cost of goods sold |
|
|
683 |
|
|
1,082 |
Research and development |
|
|
675 |
|
|
1,503 |
Selling, general and administrative |
|
|
2,221 |
|
|
6,084 |
Total costs and expenses |
|
|
3,579 |
|
|
8,669 |
Loss from discontinued operations |
|
|
(3,477) |
|
|
(8,281) |
Other expense, net |
|
|
— |
|
|
— |
Net loss from discontinued operations |
|
$ |
(3,477) |
|
$ |
(8,281) |
Basic and diluted net loss per common share from discontinued operations |
|
$ |
(1.07) |
|
$ |
(2.70) |
Weighted average shares used in computing basic and diluted net loss per common share |
|
|
3,264 |
|
|
3,062 |
The following table presents information related to assets and liabilities reported as discontinued operations in our condensed balance sheets:
|
|
|
|
|
|
|
|
|
September 30, |
|
December 31, |
|
|
2021 |
|
2020 |
(In thousands) |
|
|
|
|
|
|
Receivables |
|
$ |
160 |
|
$ |
— |
Prepaid expenses and other current assets |
|
|
27 |
|
|
181 |
Discontinued operations – current assets |
|
$ |
187 |
|
$ |
181 |
|
|
|
|
|
|
|
Accounts payable |
|
$ |
752 |
|
$ |
1,515 |
Accrued clinical trials expenses |
|
|
9 |
|
|
80 |
Accrued sales allowances |
|
|
— |
|
|
61 |
Other accrued liabilities |
|
|
352 |
|
|
304 |
Discontinued operations – current liabilities |
|
$ |
1,113 |
|
$ |
1,960 |
During the three and nine months ended September 30, 2020 we recognized non-cash stock-based compensation expenses of approximately $9,000 and $110,000, respectively, which is included in discontinued operations.
|